With the development of immunology and precision medicine, novel immunotherapeutic agents targeting programmed death protein 1 (PD-1) and its ligands (PD-L1 and PD-L2) have become important measures and trends in the treatment of advanced NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.